JP2012255007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012255007A5
JP2012255007A5 JP2012176112A JP2012176112A JP2012255007A5 JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5 JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5
Authority
JP
Japan
Prior art keywords
mutein
amino acid
acid sequence
peg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012176112A
Other languages
English (en)
Japanese (ja)
Other versions
JP5774557B2 (ja
JP2012255007A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012255007A publication Critical patent/JP2012255007A/ja
Publication of JP2012255007A5 publication Critical patent/JP2012255007A5/ja
Application granted granted Critical
Publication of JP5774557B2 publication Critical patent/JP5774557B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012176112A 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤 Expired - Fee Related JP5774557B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23136509P 2009-08-05 2009-08-05
US61/231,365 2009-08-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523344A Division JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Publications (3)

Publication Number Publication Date
JP2012255007A JP2012255007A (ja) 2012-12-27
JP2012255007A5 true JP2012255007A5 (OSRAM) 2013-09-26
JP5774557B2 JP5774557B2 (ja) 2015-09-09

Family

ID=43531164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤
JP2012176112A Expired - Fee Related JP5774557B2 (ja) 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Country Status (11)

Country Link
US (1) US20120201873A1 (OSRAM)
EP (2) EP2550958B1 (OSRAM)
JP (2) JP2013501033A (OSRAM)
KR (1) KR20120099371A (OSRAM)
CN (2) CN102612362A (OSRAM)
AU (2) AU2010280688A1 (OSRAM)
BR (1) BR112012002709A2 (OSRAM)
CA (1) CA2770149A1 (OSRAM)
IN (1) IN2012DN00407A (OSRAM)
RU (1) RU2012107812A (OSRAM)
WO (1) WO2011015634A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9701732B2 (en) 2011-02-28 2017-07-11 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
EP2682406B1 (en) * 2011-02-28 2018-05-09 Korea University Research and Business Foundation Fusion protein comprising albumin and a retinol-binding protein
US10064915B2 (en) 2011-02-28 2018-09-04 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
WO2013068590A1 (en) * 2011-11-11 2013-05-16 Pieris Ag Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization
EP2802341B1 (en) 2012-01-09 2019-03-06 Pieris Pharmaceuticals GmbH Methods for preventing, treating or diagnosing disorders
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN103360609B (zh) * 2013-07-16 2015-08-19 天津大学 一种双亲性的蛋白质-高分子键合体及其制备方法
CN103394094B (zh) * 2013-07-16 2015-05-13 天津大学 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
WO2017141106A1 (en) * 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
MXPA02003540A (es) 1999-10-08 2003-09-12 Nektar Therapeutics Al Corp Derivados de poli(etilenglicol) heterobifuncionales y los metodos para su preparacion.
CN101584867A (zh) * 2000-10-31 2009-11-25 瑟莫迪克斯药品公司 提高生物活性分子传递的方法和组合物
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CN101514223B (zh) 2003-04-11 2017-03-01 安特里阿比奥有限公司 位点特异性蛋白质偶联物的制备方法
EP2462896A1 (en) * 2003-07-15 2012-06-13 PR Pharmaceuticals Inc. Method for the preparation of controlled release formulations
BRPI0412211A (pt) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
AU2007280398B2 (en) * 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
US8263327B2 (en) * 2007-04-26 2012-09-11 Basf Se Enzymatic method for the production of microcapsules
ES2443537T3 (es) * 2007-07-26 2014-02-19 Aqtis Ip Bv Micropartículas que comprenden PCL y usos de las mismas
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
CA2713557C (en) * 2008-01-30 2016-06-07 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same

Similar Documents

Publication Publication Date Title
JP2012255007A5 (OSRAM)
WO2013096901A8 (en) Pharmaceutical formulations for fumagillin derivative-phf conjugates
EP3406347A3 (en) Xten conjugate compositions and methods of making same
MX368966B (es) Conjugados de proteina-polimero-farmaco.
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
NZ705384A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
JP2018015005A5 (OSRAM)
JP2010215657A5 (OSRAM)
UA114709C2 (uk) Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування
UA111820C2 (uk) Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
MX2012013375A (es) Peptido c pegilado.
JP2012509902A5 (OSRAM)
JP2010534486A5 (OSRAM)
JP2014129395A5 (OSRAM)
JP2013507132A5 (OSRAM)
JP2010202664A5 (OSRAM)
EP2621480A4 (en) CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY
HK1209045A1 (en) Pegylated oxm variants
JP2011515499A5 (OSRAM)
WO2010064252A3 (en) Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
JP2017523781A5 (OSRAM)
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins